 |
|
Screening of Newborns for Metabolic Disorders With Mass Spectrometry
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Waisbren and colleagues1 suggested that expanded newborn screening for metabolic disorders might improve outcomes for children, although their results do not unequivocally support this contention. By contrast, we2 have reported that newborn screening by tandem mass spectrometry in New South Wales, Australia, identified about 75% more infants with such disorders than did clinical diagnosis. Unlike the study of Waisbren et al, we had complete population ascertainment of all diagnosed infants born with these disorders, due to our centralized systems in Australia. Similarly increased diagnostic rates have been found elsewhere.3
If these results apply to the population of Waisbren et al in New England, as seems likely, then the comparisons of rates of various medical outcomes in screened and clinically diagnosed cases will not be valid. The clinically identified group of 33 infants might come from a larger affected group, of whom many may be alive but . . . [Full Text of this Article]
Bridget Wilcken, MBChB
The Children's Hospital at Westmead
Sydney, Australia
RELATED ARTICLES
Screening of Newborns for Metabolic Disorders With Mass Spectrometry—Reply
Susan Waisbren
JAMA. 2004;291(12):1444-1445.
EXTRACT
| FULL TEXT
Effect of Expanded Newborn Screening for Biochemical Genetic Disorders on Child Outcomes and Parental Stress
Susan E. Waisbren, Simone Albers, Steve Amato, Mary Ampola, Thomas G. Brewster, Laurie Demmer, Roger B. Eaton, Robert Greenstein, Mark Korson, Cecilia Larson, Deborah Marsden, Michael Msall, Edwin W. Naylor, Siegfried Pueschel, Margretta Seashore, Vivian E. Shih, and Harvey L. Levy
JAMA. 2003;290(19):2564-2572.
ABSTRACT
| FULL TEXT
|
